HBsAg Testing in Hepatitis B Diagnosis and Management

Introduction to HBsAg Testing

The American Association for the Study of Liver Diseases recommends qualitative HBsAg testing for initial diagnosis of hepatitis B infection, as it provides a binary positive/negative result to diagnose active HBV infection 1
Quantitative HBsAg measures the exact concentration in IU/mL and is used for specialized monitoring of treatment response and predicting disease outcomes, as suggested by the European Association for the Study of the Liver 1

Persistence of HBsAg beyond 6 months is adequate for diagnosing chronic hepatitis B (CHB), distinguishing chronic from acute infection, according to the American Association for the Study of Liver Diseases 1
Low HBsAg levels (<1000 IU/mL) combined with low HBV DNA (<2000 IU/mL) are associated with decreased risk of hepatocellular carcinoma and increased likelihood of HBsAg loss in HBeAg-negative patients, as reported by the European Association for the Study of the Liver 1

During peginterferon alfa therapy, absence of decline in HBsAg and HBV DNA by week 12 is a robust predictor of non-response and provides justification to stop therapy, as recommended by the American Association for the Study of Liver Diseases 1
Quantitative HBsAg declines more slowly during nucleoside/nucleotide analogue therapy compared to peginterferon, and its value in monitoring long-term nucleoside/nucleotide treatment remains unclear, according to the European Association for the Study of the Liver 1

HBV DNA quantification measures active viral replication and is the primary marker for treatment decisions, with thresholds of ≥20,000 IU/mL for HBeAg-positive CHB and ≥2,000 IU/mL for HBeAg-negative CHB, as suggested by the Infectious Diseases Society of America 4
HBV DNA is critical for distinguishing HBeAg-negative CHB from inactive carrier state, as it is the only marker of viral replication that can be monitored in these patients, according to the American Association for the Study of Liver Diseases 4

The American Association for the Study of Liver Diseases recommends ordering qualitative HBsAg for initial diagnosis of hepatitis B infection, screening asymptomatic patients from endemic regions, and confirming chronic infection (persistence beyond 6 months) 1
Quantitative HBsAg should be ordered for monitoring peginterferon alfa therapy response, assessing prognosis in HBeAg-negative patients, and evaluating HCC risk stratification, as recommended by the European Association for the Study of the Liver 1

The American Association for the Study of Liver Diseases warns against confusing HBsAg (surface antigen) with anti-HBs (surface antibody), as HBsAg indicates active infection while anti-HBs indicates immunity or recovery 3
Quantitative HBsAg assays require validation before routine use, and individual patients should be monitored with the same assay over time, as suggested by the European Association for the Study of the Liver 1